Owners, management and financials
CVR: 24257924
Secondary names: NOVO PHARMACEUTICALS A/S, NOVO FARMAKA A/S, NOVO NORDISK FARMAKA DANMARK A/S
Previous names: NOVO FARMAKA A/S
DKK -53,000
Gross profit
Net result: DKK 2,074,000
NOVO NORDISK A/S (100%)
CVR · view owners
Anders Rytter Mikkelsen
Board: Naja Eilers Barrisøe (chair) and 2 members
CVR · view management
Active
Founded 4 April 1974
CVR · view overview
0 employees
Annual report 2025 · average
Director role ended: Peter Bøggild
CVR · 12/05/2026
View the full event history
NOVO NORDISK PHARMACEUTICALS A/S is a Danish company of the type Aktieselskab based in Bagsværd, founded in 1974. The company is registered under the industry Anden finansiel formidling i.a.n.. The company was previously named NOVO FARMAKA A/S. The management consists of Anders Rytter Mikkelsen. The board consists of Naja Eilers Barrisøe (chair), Linette Tangsgaard Nielsen and Thomas Rask Nielsen. The company is owned by NOVO NORDISK A/S. According to the 2025 annual report, the company had an average of 0 employees. In 2025, the company reported a gross profit of DKK -53,000 and a net result of DKK 2,074,000 compared with DKK 6,918,000 the year before. Equity in the 2025 report amounted to DKK 12,325,000.
Selskabtes formål er at drive fremstilling af og handel med lægemidler og dermed beslægtede produkter og anden dermed i forbindelse stående virksomhed, herunder forskning og investering.
Source: annual reports filed with the Danish Business Authority.
| Period | Revenue | Profit/Loss | Total Assets | Equity | Employees | Report |
|---|---|---|---|---|---|---|
| 202501/01/2025 – 31/12/2025 | - | 2.1M | 30.5M | 12.3M | 0 | |
| 202401/01/2024 – 31/12/2024 | - | 6.9M | 26.3M | 10.3M | 0 | |
| 202301/01/2023 – 31/12/2023 | - | -2.3M | 111.2M | 103.3M | - | |
| 202201/01/2022 – 31/12/2022 | - | -5.4M | 210.2M | 105.6M | - | |
| 202101/01/2021 – 31/12/2021 | 24.7M | 1.3M | 3B | 2.9B | - | |
| 202001/01/2020 – 31/12/2020 | - | -2.4M | 3B | 2.8B | - | |
| 201901/01/2019 – 31/12/2019 | - | 3.7M | 15.6M | 15.6M | - | |
| 201801/01/2018 – 31/12/2018 | - | -2M | 11.9M | 11.8M | - | |
| 201701/01/2017 – 31/12/2017 | - | -2.3M | 13.9M | 13.8M | - | |
| 201601/01/2016 – 31/12/2016 | - | 1.7M | 16.1M | 16.1M | - | |
| 201501/01/2015 – 31/12/2015 | - | 1.9M | 14.4M | 14.4M | - | |
| 201401/01/2014 – 31/12/2014 | - | 3.2M | 12.6M | 12.5M | - |
Compared to 20.409 companies in Anden finansiel formidling i.a.n.
Comparison is based on industry median values
Screen owners and management against the Danish FSA's official PEP lists
Combine filters on financials, industry, geography, property and risk, and instantly see which companies match.
Try company screeningThe CVR number of NOVO NORDISK PHARMACEUTICALS A/S is 24257924.
NOVO NORDISK PHARMACEUTICALS A/S is owned by NOVO NORDISK A/S.
The management of NOVO NORDISK PHARMACEUTICALS A/S consists of Anders Rytter Mikkelsen.
The board of NOVO NORDISK PHARMACEUTICALS A/S consists of Naja Eilers Barrisøe, Linette Tangsgaard Nielsen and Thomas Rask Nielsen, with Naja Eilers Barrisøe as chair.
In 2025, NOVO NORDISK PHARMACEUTICALS A/S reported a gross profit of DKK -53,000.
NOVO NORDISK PHARMACEUTICALS A/S had an average of 0 employees in the 2025 financial year according to the annual report.
Claim this page to add your logo and social links. Free to get started.
Contact info changed: new phone: 44448888 (October 9, 2026).
As of October 8, 2026, Thomas Rask Nielsen has joined the board of directors of NOVO NORDISK PHARMACEUTICALS A/S.
As of October 8, 2026, John Francis Kuckelman has left the board of directors of NOVO NORDISK PHARMACEUTICALS A/S.
NOVO NORDISK PHARMACEUTICALS A/S has published its annual report for 2025. Gross profit came to DKK -53,000, and the net result was DKK 2,074,000.
Contact info changed: new phone: 44448888 (May 13, 2026).
As of May 12, 2026, Anders Rytter Mikkelsen is registered as director of NOVO NORDISK PHARMACEUTICALS A/S.
As of May 12, 2026, Peter Bøggild has stepped down as director of NOVO NORDISK PHARMACEUTICALS A/S.
As of December 8, 2025, Naja Eilers Barrisøe has joined the board of directors of NOVO NORDISK PHARMACEUTICALS A/S.
As of December 8, 2025, Karsten Munk Knudsen has left the board of directors of NOVO NORDISK PHARMACEUTICALS A/S.
NOVO NORDISK PHARMACEUTICALS A/S has published its annual report for 2024. Gross profit came to DKK -46,000, and the net result was DKK 6,918,000.
NOVO NORDISK PHARMACEUTICALS A/S has published its annual report for 2023. Gross profit came to DKK -46,000, and the net result was DKK -2,258,000.
As of May 23, 2024, John Francis Kuckelman has joined the board of directors of NOVO NORDISK PHARMACEUTICALS A/S.
As of May 23, 2024, Kristine Aachmann Bethe has left the board of directors of NOVO NORDISK PHARMACEUTICALS A/S.
As of June 30, 2023, Kristine Aachmann Bethe has joined the board of directors of NOVO NORDISK PHARMACEUTICALS A/S.
As of June 30, 2023, Tomas Haagen has left the board of directors of NOVO NORDISK PHARMACEUTICALS A/S.
NOVO NORDISK PHARMACEUTICALS A/S has published its annual report for 2022. Gross profit came to DKK 6,218,000, and the net result was DKK -5,443,000.
NOVO NORDISK PHARMACEUTICALS A/S has published its annual report for 2021. Revenue came to DKK 24,653,000, and the net result was DKK 1,330,000.
NOVO NORDISK PHARMACEUTICALS A/S has published its annual report for 2020. The net result was DKK -2,368,000.
As of May 12, 2021, DELOITTE STATSAUTORISERET REVISIONSPARTNERSELSKAB has been appointed auditor of NOVO NORDISK PHARMACEUTICALS A/S.
As of May 12, 2021, PRICEWATERHOUSECOOPERS STATSAUTORISERET REVISIONSPARTNERSELSKAB has stepped down as auditor of NOVO NORDISK PHARMACEUTICALS A/S.
As of December 15, 2020, Linette Tangsgaard Nielsen has joined the board of directors of NOVO NORDISK PHARMACEUTICALS A/S.
As of December 15, 2020, Lene Moth Bang has left the board of directors of NOVO NORDISK PHARMACEUTICALS A/S.
NOVO NORDISK PHARMACEUTICALS A/S has published its annual report for 2019. The net result was DKK 3,722,000.
NOVO NORDISK PHARMACEUTICALS A/S has published its annual report for 2018. The net result was DKK -1,984,000.
As of October 1, 2018, Tomas Haagen has joined the board of directors of NOVO NORDISK PHARMACEUTICALS A/S.
As of October 1, 2018, Ole Falvig Ramsby has left the board of directors of NOVO NORDISK PHARMACEUTICALS A/S.
NOVO NORDISK PHARMACEUTICALS A/S has published its annual report for 2017. The net result was DKK -2,285,000.
As of April 25, 2018, Karsten Munk Knudsen has joined the board of directors of NOVO NORDISK PHARMACEUTICALS A/S.
As of April 25, 2018, Jesper Brandgaard has left the board of directors of NOVO NORDISK PHARMACEUTICALS A/S.
As of April 25, 2018, Peter Bøggild is registered as director of NOVO NORDISK PHARMACEUTICALS A/S.
As of April 25, 2018, Karsten Munk Knudsen has stepped down as director of NOVO NORDISK PHARMACEUTICALS A/S.
As of June 1, 2017, Lene Moth Bang has joined the board of directors of NOVO NORDISK PHARMACEUTICALS A/S.
As of June 1, 2017, Lars Fruergaard Jørgensen has left the board of directors of NOVO NORDISK PHARMACEUTICALS A/S.
NOVO NORDISK PHARMACEUTICALS A/S has published its annual report for 2016. The net result was DKK 1,694,000.
NOVO NORDISK PHARMACEUTICALS A/S has published its annual report for 2015. The net result was DKK 1,879,000.
As of April 30, 2015, Lars Fruergaard Jørgensen has joined the board of directors of NOVO NORDISK PHARMACEUTICALS A/S.
As of April 30, 2015, Kåre Schultz has left the board of directors of NOVO NORDISK PHARMACEUTICALS A/S.
NOVO NORDISK PHARMACEUTICALS A/S has published its annual report for 2014. The net result was DKK 3,150,000.
NOVO NORDISK PHARMACEUTICALS A/S has published its annual report for 2013.
As of July 1, 2014, Karsten Munk Knudsen is registered as director of NOVO NORDISK PHARMACEUTICALS A/S.
As of July 1, 2014, Lars Green has stepped down as adm. dir. of NOVO NORDISK PHARMACEUTICALS A/S.
NOVO NORDISK PHARMACEUTICALS A/S has published its annual report for 2012.
As of July 1, 2011, PRICEWATERHOUSECOOPERS STATSAUTORISERET REVISIONSPARTNERSELSKAB has been appointed auditor of NOVO NORDISK PHARMACEUTICALS A/S.
As of July 1, 2011, A/S PSE NR. 4820 has stepped down as auditor of NOVO NORDISK PHARMACEUTICALS A/S.
As of April 27, 2006, A/S PSE NR. 4820 has been appointed auditor of NOVO NORDISK PHARMACEUTICALS A/S.
As of April 27, 2006, Pricewaterhouse Coopers has stepped down as auditor of NOVO NORDISK PHARMACEUTICALS A/S.
As of June 22, 2005, Kåre Schultz has joined the board of directors of NOVO NORDISK PHARMACEUTICALS A/S.
As of June 22, 2005, Jesper Brandgaard has joined the board of directors of NOVO NORDISK PHARMACEUTICALS A/S.
As of June 22, 2005, Lars Rebien Sørensen has left the board of directors of NOVO NORDISK PHARMACEUTICALS A/S.
As of June 22, 2005, Lars Green is registered as adm. dir. of NOVO NORDISK PHARMACEUTICALS A/S.
As of June 22, 2005, Jesper Brandgaard has stepped down as adm. dir. of NOVO NORDISK PHARMACEUTICALS A/S.
As of June 21, 2001, Pricewaterhouse Coopers has been appointed auditor of NOVO NORDISK PHARMACEUTICALS A/S.
As of June 21, 2001, A/S PSE NR. 4820 has stepped down as auditor of NOVO NORDISK PHARMACEUTICALS A/S.
As of November 30, 2000, Lars Rebien Sørensen has joined the board of directors of NOVO NORDISK PHARMACEUTICALS A/S.
As of November 30, 2000, Kurt Anker Nielsen has left the board of directors of NOVO NORDISK PHARMACEUTICALS A/S.
As of November 30, 2000, Mads Øvlisen has left the board of directors of NOVO NORDISK PHARMACEUTICALS A/S.
As of November 30, 2000, Jesper Brandgaard is registered as adm. dir. of NOVO NORDISK PHARMACEUTICALS A/S.
As of November 30, 2000, Kurt Anker Nielsen has stepped down as director of NOVO NORDISK PHARMACEUTICALS A/S.
As of May 30, 1997, Kurt Anker Nielsen has joined the board of directors of NOVO NORDISK PHARMACEUTICALS A/S.
As of May 30, 1997, Ole Falvig Ramsby has joined the board of directors of NOVO NORDISK PHARMACEUTICALS A/S.
As of May 30, 1997, Mads Ravn Sørensen has left the board of directors of NOVO NORDISK PHARMACEUTICALS A/S.
As of May 30, 1997, Bent Hauerberg has left the board of directors of NOVO NORDISK PHARMACEUTICALS A/S.
As of March 7, 1995, PRICE WATERHOUSE DANMARK ApS has stepped down as auditor of NOVO NORDISK PHARMACEUTICALS A/S.
As of March 7, 1995, Mads Øvlisen has stepped down as director of NOVO NORDISK PHARMACEUTICALS A/S.
As of July 6, 1990, has stepped down as auditor of NOVO NORDISK PHARMACEUTICALS A/S.
On February 27, 1990, the company changed its name from NOVO FARMAKA A/S to NOVO NORDISK PHARMACEUTICALS A/S.
As of April 4, 1974, PRICE WATERHOUSE DANMARK ApS has been appointed auditor of NOVO NORDISK PHARMACEUTICALS A/S.
As of April 4, 1974, A/S PSE NR. 4820 has been appointed auditor of NOVO NORDISK PHARMACEUTICALS A/S.
As of April 4, 1974, has been appointed auditor of NOVO NORDISK PHARMACEUTICALS A/S.
As of April 4, 1974, Mads Ravn Sørensen has joined the board of directors of NOVO NORDISK PHARMACEUTICALS A/S.
As of April 4, 1974, Mads Øvlisen has joined the board of directors of NOVO NORDISK PHARMACEUTICALS A/S.
As of April 4, 1974, Bent Hauerberg has joined the board of directors of NOVO NORDISK PHARMACEUTICALS A/S.
As of April 4, 1974, Kurt Anker Nielsen is registered as director of NOVO NORDISK PHARMACEUTICALS A/S.
As of April 4, 1974, Mads Øvlisen is registered as director of NOVO NORDISK PHARMACEUTICALS A/S.
As of April 4, 1974, NOVO NORDISK A/S is registered as an owner of NOVO NORDISK PHARMACEUTICALS A/S with an ownership share of 100%.
NOVO NORDISK PHARMACEUTICALS A/S was founded on April 4, 1974.
Companies in the same industry and area
CVR 21244643
CVR 43221124
CVR 36951982
CVR 16257281
CVR 45840832
